Key Points
- CEO sale: Acumen CEO Daniel J. O'Connell sold 37,755 shares on Jan. 7 at an average of $1.99 (≈$75,132), leaving him with about 619,982 shares, and the transaction was disclosed in an SEC filing.
- Broader insider selling: Other executives also sold stock Jan. 5–7 — CFO Matt Zuga (14,905 shares), COO Russell Barton (9,318 shares) and Eric Siemers (10,834 shares) — indicating multiple management members reduced positions.
- Market and analyst context: ABOS traded around $1.99 (up ~1.5%) with a market cap near $120.5M; analysts show a consensus "Moderate Buy" and an average price target of $6.75 despite the company reporting negative EPS.
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) CFO Matt Zuga sold 5,100 shares of Acumen Pharmaceuticals stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $1.97, for a total transaction of $10,047.00. Following the sale, the chief financial officer owned 222,644 shares of the company's stock, valued at approximately $438,608.68. The trade was a 2.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Matt Zuga also recently made the following trade(s):
- On Wednesday, January 7th, Matt Zuga sold 5,805 shares of Acumen Pharmaceuticals stock. The stock was sold at an average price of $1.99, for a total transaction of $11,551.95.
- On Monday, January 5th, Matt Zuga sold 4,000 shares of Acumen Pharmaceuticals stock. The stock was sold at an average price of $1.96, for a total transaction of $7,840.00.
Acumen Pharmaceuticals Trading Up 1.5%
NASDAQ ABOS opened at $1.99 on Thursday. Acumen Pharmaceuticals, Inc. has a 1 year low of $0.86 and a 1 year high of $2.46. The company has a debt-to-equity ratio of 0.29, a current ratio of 6.02 and a quick ratio of 6.02. The company has a market capitalization of $120.53 million, a PE ratio of -0.90 and a beta of 0.23. The company has a fifty day moving average of $1.96 and a 200 day moving average of $1.67.
Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.19. Research analysts forecast that Acumen Pharmaceuticals, Inc. will post -1.56 earnings per share for the current year.
Institutional Trading of Acumen Pharmaceuticals
Institutional investors and hedge funds have recently made changes to their positions in the business. Jacobs Levy Equity Management Inc. acquired a new position in shares of Acumen Pharmaceuticals during the 3rd quarter worth approximately $27,000. Marex Group plc acquired a new stake in Acumen Pharmaceuticals in the 2nd quarter valued at $39,000. AQR Capital Management LLC purchased a new stake in Acumen Pharmaceuticals in the 1st quarter worth $46,000. Qube Research & Technologies Ltd raised its position in Acumen Pharmaceuticals by 160.0% during the second quarter. Qube Research & Technologies Ltd now owns 57,559 shares of the company's stock worth $67,000 after acquiring an additional 35,424 shares during the period. Finally, Invesco Ltd. lifted its holdings in Acumen Pharmaceuticals by 544.1% during the first quarter. Invesco Ltd. now owns 127,798 shares of the company's stock valued at $141,000 after purchasing an additional 107,956 shares in the last quarter. 71.01% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
ABOS has been the subject of a number of analyst reports. Bank of America decreased their price target on Acumen Pharmaceuticals from $9.00 to $8.00 and set a "buy" rating for the company in a report on Tuesday, November 18th. Wall Street Zen upgraded shares of Acumen Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Sunday, December 21st. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Acumen Pharmaceuticals in a report on Tuesday, October 14th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Acumen Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $6.75.
Read Our Latest Stock Report on Acumen Pharmaceuticals
Key Acumen Pharmaceuticals News
Here are the key news stories impacting Acumen Pharmaceuticals this week:
- Negative Sentiment: CEO Daniel J. O'Connell sold three blocks between Jan. 5–7 totaling 47,506 shares (largest single-day block ~37,755 on Jan. 7), reducing his stake by ~5.7% and raising roughly $75k on the largest sale. CEO still holds a sizable position (~620k shares). SEC Filing
- Negative Sentiment: CFO Matt Zuga sold three tranches on Jan. 5–7 totaling 14,905 shares (~1.73%–2.61% reductions per trade), raising roughly $29k across the period and leaving him with ~216k–227k shares. SEC Filing
- Negative Sentiment: COO Russell Barton sold three tranches on Jan. 5–7 totaling 9,318 shares, trimming his holding by a few percent and raising roughly $18k. SEC Filing
- Negative Sentiment: Insider Eric Siemers sold two tranches (4,000 and 6,834 shares) on Jan. 5–6, reducing his stake by ~2–4% and raising ~ $21k. SEC Filing
About Acumen Pharmaceuticals
(
Get Free Report)
Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies for neurodegenerative diseases. Leveraging a proprietary drug discovery platform that integrates chemoproteomics, high-throughput screening and computational chemistry, the company seeks to identify and optimize compounds that selectively modulate pathological protein aggregation. Its approach is designed to address the underlying biology of conditions such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and related proteinopathies.
The company's pipeline comprises multiple lead candidates at various stages of preclinical and early clinical development.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
